BioSpace News Archive

Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the fourth quarter and year ended December 31, 2022.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and year ended December 31, 2022.

Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a Targeted Oncology Panel at the Cowen and Company 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:10 p.m. ET.

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

Azenta, Inc. announced that Company management will participate in two upcoming investor conferences.

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”) today announced that it will report the Company’s fourth quarter 2022 financial results on Thursday, March 9, 2023 after the close of the U.S. financial markets.

Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to batiraxcept for the treatment of pancreatic ductal adenocarcinoma cancer (PDAC).

Cumberland Pharmaceuticals Inc., a specialty pharmaceuticals company, announced that it will release its annual 2022 financial results and provide a company update after the market closes on Tuesday, March 7, 2023.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2022 and highlighted recent corporate progress.

Spruce Biosciences, Inc. (Nasdaq: SPRB) today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 2:40 PM ET.